These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Parallel double-blind study of pergolide in Parkinson's disease. Jankovic J; Orman J Adv Neurol; 1987; 45():551-4. PubMed ID: 3548265 [No Abstract] [Full Text] [Related]
24. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. Chaná P; Fierro A; Reyes-Parada M; Sáez-Briones P Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590 [TBL] [Abstract][Full Text] [Related]
25. An open trial of controlled release carbidopa/L-dopa (sinemet CR) for the treatment of mild-to-moderate Parkinson's disease. Friedman JH; Lannon MC Clin Neuropharmacol; 1989 Jun; 12(3):220-3. PubMed ID: 2743346 [TBL] [Abstract][Full Text] [Related]
26. Sinemet - 25/100. Med Lett Drugs Ther; 1980 Jun; 22(12):51. PubMed ID: 7374623 [No Abstract] [Full Text] [Related]
27. Lisuride and pergolide in Parkinson's disease. Lang AE; Sheehy MP; Quinn NP; Brincat S; Marsden CD; Parkes D Adv Neurol; 1983; 37():109-20. PubMed ID: 6858769 [No Abstract] [Full Text] [Related]
28. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222 [TBL] [Abstract][Full Text] [Related]
29. Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group. Wolters EC; Horstink MW; Roos RA; Jansen EN Adv Neurol; 1993; 60():648-52. PubMed ID: 8420204 [No Abstract] [Full Text] [Related]
30. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease. Lieberman AN; Neophytides A; Leibowitz M; Gopinathan G; Pact V; Walker R; Goodgold A; Goldstein M Adv Neurol; 1983; 37():95-108. PubMed ID: 6858782 [TBL] [Abstract][Full Text] [Related]
31. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment. Zimmerman TR; Sage JI; Lang AE; Mark MH Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678 [TBL] [Abstract][Full Text] [Related]
32. Pergolide mesylate: four years experience in Parkinson's disease. Tanner CM; Goetz CG; Glantz RH; Klawans HL Adv Neurol; 1987; 45():547-9. PubMed ID: 3825732 [No Abstract] [Full Text] [Related]
33. Bromocriptine and levodopa (with or without carbidopa) in parkinsonism. Kartzinel R; TEYCHENNE P; Gillespie MM; Perlow M; Gielen AC; Sadowsky DA; Calne DB Lancet; 1976 Aug; 2(7980):272-5. PubMed ID: 59850 [TBL] [Abstract][Full Text] [Related]
34. An analysis of treatment options and outcome in patients with Parkinson's disease and severe dyskinesias. Mark MH; Sage JI Ann Clin Lab Sci; 1994; 24(1):12-21. PubMed ID: 8147565 [TBL] [Abstract][Full Text] [Related]
35. Efficacy of pergolide and mesulergine. Lieberman AN; Gopinathan G; Neophytides A Eur Neurol; 1986; 25(2):86-90. PubMed ID: 3948891 [TBL] [Abstract][Full Text] [Related]
37. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Brannan T; Yahr MD Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264 [TBL] [Abstract][Full Text] [Related]
38. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect. Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340 [TBL] [Abstract][Full Text] [Related]